A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren\'s syndrome.
Epistemonikos ID: 43a594f05bb612e9fd5af30f8fceed5f1c847d47
First added on: Jan 30, 2026